Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaqu…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $2.41 | $1.65 | $2.03 |
| Estimado | $2.24 | $2.15 | $1.65 | $2.00 |
| Sorpresa | — | +12.1% | +0.0% | +1.5% |
| Métrica | NVS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 78.8% | 57.4% | +21.4% |
| Operating Margin | 32.4% | -34.4% | +66.7% |
| Net Margin | 25.6% | -32.5% | +58.1% |
| FCF Margin | 32.3% | -12.6% | +44.9% |
| ROE | 30.3% | -39.2% | +69.5% |
| ROA | 12.6% | -30.9% | +43.5% |
| Current Ratio | 1.12 | 2.73 | -1.61 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 12.6% | — |
| ✓Flujo de caja operativo positivo | $19.1B | $17.6B |
| ✓Rentabilidad sobre activos al alza | 12.6% | 11.7% |
| ✓Caja operativa/activos supera al ROA | 17.3% | ROA 12.6% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 1.12 | 1.04 |
| ✓Sin aumentar el nº de acciones | 1,955M | 2,035M |
| ✓Margen bruto al alza | 78.8% | 77.3% |
| ✗Rotación de activos al alza | 0.49 | 0.49 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 32.3% |
| ✓ROCE > 10 % | 21.1% |
| ✓Ventas > 5 %/año (3 años) | 8.9% |
| ✓Deuda neta/EBITDA < 3x | 0.9x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 23.4% |
NOVARTIS AG cotiza a 150.62 USD y tiene una capitalización bursátil de $286.3B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud